How the Hell do I Prioritize Work, Blog & Find Balance?

Both Sides of the Table

I don’t know Ezra yet but since he’s taking the time to blog (which I hugesly respect) and share thoughts I thought I’d take him up on his challenge and also spill the beans on my secrets. On blogging I blog because I love it. My other secret on blogging?

Entrepreneurshit. The Blog Post on What It’s Really Like.

Both Sides of the Table

It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities. Late night Mexican food. Beers. Airports. Delays. I left on a Sunday. I had to miss a full day with my family, camping in the mountains.

Trending Sources

HipGeo Launches Updated iPhone Travel Blogging App

socalTECH

The company said the redesign came after finding that users were interested in using its tools to create blog-like travel and trip journals, rather than the original, animated slideshows the tool provided. networking social blogging travel iphone hipgeo

Blogging for the Hell of It, Not Blogging to Stay Relevant

Both Sides of the Table

I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too. I guess it’s just a reality of blogging and I accept that. I like “single take” blogging.

The Winners of the 2017 Xconomy Awards Are…

Xconomy

We are excited to announce the recipients of the first-ever Xconomy Awards.

Ideas 31

Expanding Tissue and Squeezing Cells: Meet Xconomy’s Young Innovator Award Finalists

Xconomy

View the Slideshow The finalists in the Young Innovator category of the 2017 Xconomy Awards show that it’s never too early in life to start a company or invent a new technology.

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type

Xconomy

For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in which the cancer originated.

Countering Cybersecurity Turnover: 57 Companies That Do It Best

Xconomy

What does it take to keep highly skilled cybersecurity employees? Salary and benefits are table-stakes.

Woodcock: New Approvals Show FDA is Adapting to Precision Medicine

Xconomy

The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments.

Unanimous Advice To FDA: Approve Landmark CAR-T Cancer Therapy

Xconomy

The first ever approval of a new kind of cancer immunotherapy called CAR-T is one step closer.

Amid Gender Gap Talk, Mentor Network Emerges For Women In Health, Bio

Xconomy

It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference. There has been plenty of talk since about closing biotech’s notable gender gap. At this year’s J.P

Novartis: CAR-T Results In One Month, Or No Charge. Why One Month?

Xconomy

Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it fails to help patients within a month.

Blockchain, Banks & the New Web: Q&A With Ethereum Co-founder Lubin

Xconomy

Ethereum co-founder Joe Lubin is calm and soft-spoken when he shares his vision of how blockchain technology and digital currencies could transform the Internet, the global economy, and many aspects of our daily lives. But what he’s talking about could become a raging tempest, and it’s worth paying attention to—especially given the vast sums of money pouring into the sector. Companies have raised more than $1.25

Web 23

Xconomy Awards: The Finalists Are….

Xconomy

Boston Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Life Sciences xconomyawardsboston

Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000

Xconomy

Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine.

Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More

Xconomy

The CEO of a major U.S. pharmaceutical company was in the news this week, but for a change not because of the cost of drugs. Merck CEO Kenneth Frazier (pictured) was the first of what quickly became a line of CEOs to exit President Trump’s manufacturing council, leading to its dissolution altogether.

News 28

Bio Roundup: GOP Vote-a-Rama, Immunotherapy Setbacks, Pharma Revamps

Xconomy

Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Accelerator Corp.

Study 30

Stand up to “Bully” Trump: Bio CEOs Levin, Holtzman Call to Their Peers

Xconomy

Biotech CEOs Jeremy Levin and Steve Holtzman have watched the violence in Charlottesville, VA , and its continuing aftermath with disgust. But they aren’t just upset about the rally, the violence and death, and President Trump’s equivocating blame of “many sides.” Levin, of Ovid Therapeutics (NASDAQ: OVID ), and Holtzman, of Decibel Therapeutics, have been disappointed with their peers.

Power to the Patient: Meet Xconomy’s Patient Partnership Award Finalists

Xconomy

It’s clear at this point that patients are no longer just subjects in clinical trials.

The Xconomy Roadmap: Top 15 Innovation Areas to Watch (and Disrupt)

Xconomy

View the Slideshow It is a time of great transitions in the technology and business world. Key advances in areas like machine intelligence, agriculture, and healthcare seem poised to transform society—and everyday life.

News 34

ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity

Xconomy

[ Note: Ben Fidler coauthored this report.] The American Society of Clinical Oncology conference is wrapping up, and the closely-watched medical meeting-slash-hype machine produced its usual array of data.

VC Confidence Holds Steady in Quarterly Survey, But Reasons Change

Xconomy

Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More

Xconomy

Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Affordable Care Act Alnylam Pharmaceuticals Andrew Witty Arrowhead Pharmaceuticals Bill Cassidy Biogen Biotech Burrill & Co.

Gottlieb Reportedly On Tap to Lead FDA, and Biopharma Exhales

Xconomy

According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon.

News 34

Low-Hanging Fruit Gone, Ag & Food Tech Investors Pay More for Deals

Xconomy

Food delivery startups are catching on with more consumers, and that demand is whetting investor appetites. The $400 million that grocery delivery startup Instacart raised in March marked the largest deal for a U.S. food technology company in the first half of the year, according to new data from online investment marketplace AgFunder.

Black Fellowship Students Headed From HBCUs to VC Boardrooms

Xconomy

In mid-October, eleven college students will be flying to California for an opportunity that would be the envy of any Ivy League MBA candidate—they’ll meet the venture capital firm partners who will personally mentor them throughout the school year.

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy

Xconomy

It’s not a stretch to say that Greta Oberhofer is alive thanks to the genetically modified cell therapy called CAR-T. At three and a half months old, she was diagnosed with acute lymphoblastic leukemia, or ALL, an aggressive blood cancer. At 10 months old, she had a bone marrow transplant, which required chemotherapy. She had a bad reaction: Her kidney and liver shut down, and fluid built up in her heart and lungs. She was on a breathing machine.

Should You Bother Targeting the Tech Blogs for Your PR Campaigns?

Both Sides of the Table

6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs.

Boston Is Arguably the Heart of Biotech. But Who Makes It So? Have Your Say.

Xconomy

By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy , to prolong their life. Immunotherapy could further entrench itself as a mainstay of cancer treatment.

Introducing Xconomy Voices (Podcast), Episode 1: Mary Lou Jepsen

Xconomy

It’s always been Xconomy’s mission to reach audiences—both here on our website, and at our many live events around the country—with deep insights into the innovation process, divined from experts embedded in the world’s most important hubs of high-tech entrepreneurship.

Bio Roundup: CRISPR Advances, Obamacare Lives, FDA Nods & More

Xconomy

Gene editing took an important step this week when a group of U.S. researchers used CRISPR-Cas9 technology to correct a genetic error in dozens of human embryos without complications. It’s a significant achievement, but amidst the hype, it’s worth cautioning just how much work has to be done before the technology leads to a safe and effective human therapeutic. Years of clinical testing, and likely unforeseen twists and turns, lay ahead, with many more biological mysteries to solve along the way.

Private Equity Investors Have $740 Billion to Spend, Driving Valuations

Xconomy

Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle Seattle blog main Texas blog main Wisconsin blog main Apollo Investment Fund Dylan Cox Limited Partners M&A New Enterprise Associates PitchBook Private Equity VC

Bio Roundup: $1B Deals, Data Bumps, Acorda’s Lumps, Generic OKs & More

Xconomy

With President Trump holed up in New Jersey, rattling his saber at Kim Jong-un and Mitch McConnell and ignoring his own commission’s advice on the opioid crisis, there was still life sciences news from the nation’s capital. The FDA reported that generic drug approvals are set to hit a record ; the agency under Commissioner Scott Gottlieb has moved this summer to increase generic competition and lower the nation’s high drug prices.